文献速递冠心病血脂与心血管预防

冠状动脉CTA高危斑块检测用于稳定性胸痛患者风险分层的PROMISE试验二次分析

Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

本研究为PROMISE随机临床试验的预设嵌套观察性队列分析,纳入4415例接受冠状动脉CTA的稳定性胸痛门诊患者,随访中位25个月。结果显示,高危斑块与主要不良心血管事件(MACE)独立相关(调整后HR 1.72),尤其在非阻塞性冠心病、女性和年轻患者中风险更高,但绝对MACE率低且阳性预测值有限。

要点

  • 冠状动脉CTA检出高危斑块与MACE独立相关,调整ASVD评分和显著狭窄后aHR为1.72。
  • 高危斑块在非阻塞性冠心病患者中显著增加MACE风险(aHR 4.31)。
  • 女性和年轻患者中高危斑块对MACE的预测作用更强。

核心结论

  • 冠状动脉CTA发现的高危斑块与稳定性胸痛门诊患者未来MACE独立相关,可能作为额外风险分层工具,尤其适用于非阻塞性冠心病、年轻患者和女性。

研究设计与样本

  • PROMISE随机临床试验的预设嵌套观察性队列研究,纳入4415例稳定性症状性门诊患者,均接受冠状动脉CTA,中位随访25个月。

主要发现

  • 高危斑块检出率为15.3%,显著狭窄为6.3%,MACE发生率为3%(131例事件)。
  • 高危斑块组MACE发生率6.4% vs 无高危斑块组2.4%(HR 2.73,95%CI 1.89-3.93)。
  • 调整ASCVD风险评分和显著狭窄后,高危斑块仍与MACE相关(aHR 1.72,95%CI 1.13-2.62)。
  • 加入高危斑块评估显著改善连续净重分类指数(0.34,95%CI 0.02-0.51)。
  • 非阻塞性冠心病患者中,高危斑块组aHR 4.31(95%CI 2.25-8.26),无高危斑块组aHR 2.64(95%CI 1.49-4.69)。

关键数值与推荐

  • 高危斑块定义为正性重构、低CT衰减或餐巾环征。
  • 主要终点为死亡、心肌梗死或不稳定心绞痛的复合终点。

临床怎么用

  • 对稳定性胸痛患者行冠状动脉CTA时评估高危斑块,可辅助风险分层,尤其非阻塞性冠心病、女性和年轻患者。

局限性

  • 绝对MACE发生率低且高危斑块阳性预测值有限,限制了发现的重要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Coronary computed tomographic angiography (coronary CTA) can characterize coronary artery disease, including high-risk plaque. A noninvasive method of identifying high-risk plaque before major adverse cardiovascular events (MACE) could provide practice-changing optimizations in coronary artery disease care. OBJECTIVE: To determine whether high-risk plaque detected by coronary CTA was associated with incident MACE independently of significant stenosis (SS) and cardiovascular risk factors. DESIGN, SETTING, AND PARTICIPANTS: This prespecified nested observational cohort study was part of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. All stable, symptomatic outpatients in this trial who required noninvasive cardiovascular testing and received coronary CTA were included and followed up for a median of 25 months. EXPOSURES: Core laboratory assessment of coronary CTA for SS and high-risk plaque (eg, positive remodeling, low computed tomographic attenuation, or napkin-ring sign). MAIN OUTCOMES AND MEASURES: The primary end point was an adjudicated composite of MACE (defined as death, myocardial infarction, or unstable angina). RESULTS: The study included 4415 patients, of whom 2296 (52%) were women, with a mean age of 60.5 years, a median atherosclerotic cardiovascular disease (ASCVD) risk score of 11, and a MACE rate of 3% (131 events). A total of 676 patients (15.3%) had high-risk plaques, and 276 (6.3%) had SS. The presence of high-risk plaque was associated with a higher MACE rate (6.4% vs 2.4%; hazard ratio, 2.73; 95% CI, 1.89-3.93). This association persisted after adjustment for ASCVD risk score and SS (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.13-2.62). Adding high-risk plaque to the ASCVD risk score and SS assessment led to a significant continuous net reclassification improvement (0.34; 95% CI, 0.02-0.51). Presence of high-risk plaque increased MACE risk among patients with nonobstructive coronary artery disease relative to patients without high-risk plaque (aHR, 4.31 vs 2.64; 95% CI, 2.25-8.26 vs 1.49-4.69). There were no significant differences in MACE in patients with SS and high-risk plaque as opposed to those with SS but not high-risk plaque (aHR, 8.68 vs. 9.31; 95% CI, 4.25-17.73 vs 4.21-20.61). High-risk plaque was a stronger predictor of MACE in women (aHR, 2.41; 95% CI, 1.25-4.64) vs men (aHR, 1.40; 95% CI, 0.81-2.39) and younger patients (aHR, 2.33; 95% CI, 1.20-4.51) vs older ones (aHR, 1.36; 95% CI, 0.77-2.39). CONCLUSIONS AND RELEVANCE: High-risk plaque found by coronary CTA was associated with a future MACE in a large US population of outpatients with stable chest pain. High-risk plaque may be an additional risk stratification tool, especially in patients with nonobstructive coronary artery disease, younger patients, and women. The importance of findings is limited by low absolute MACE rates and low positive predictive value of high-risk plaque. TRIAL REGISTRATION: clinicaltrials.gov Indentifier: NCT01174550.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ferencik M, Mayrhofer T, Bittner DO, et al. Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 29322167. doi:10.1001/jamacardio.2017.4973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。